SAB Biotherapeutics (SABS) Return on Sales (2021 - 2024)

SAB Biotherapeutics' Return on Sales history runs 4 years deep, the most recent figure standing at 0.87% for Q4 2024.

• Quarterly Return on Sales fell 12.0% year-over-year to 0.87% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.25% (down 6.0% YoY) and the FY2024 annual result came in at 0.32%, down 14.0% from the prior year.
• Return on Sales was 0.87% for Q4 2024 at SAB Biotherapeutics, down from 0.3% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2022 and bottomed at 0.87% in Q4 2024.
• A 4-year average of 0.21% and a median of 0.04% in 2022 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2023 — Return on Sales sank 80 bps — and 2024, when it jumped 53 bps.
• SAB Biotherapeutics' Return on Sales stood at 0.01% in 2021, then slumped by 248 bps to 0.04% in 2022, then tumbled by 1963 bps to 0.75% in 2023, then dropped by 16 bps to 0.87% in 2024.
• Business Quant data shows SABS's Return on Sales at 0.87% in Q4 2024, 0.3% in Q3 2024, and 0.28% in Q2 2024.